Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
huRS1 Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

huRS1 Mouse

Product Name
huRS1 Mouse
Product ID
C002008
Strain Name
C57BL/6JCya-Rs1tm1(hRS1)/Cya
Backgroud
C57BL/6JCya
Status
Live Mouse
When using this mouse strain in a publication, please cite “huRS1 Mouse (Catalog C002008) were purchased from Cyagen.”
HUGO-GT Humanized Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
HUGO-GT Humanized Models

Basic Information

Related Resource

Basic Information
Gene Name
RS1
Gene Alias
RS, XLRS1
NCBI ID
6247 (Human)
Chromosome
Chr X (Human)
MGI ID
MGI:1336189
Datasheet
Click here to download >>

Strain Description

X-linked juvenile retinoschisis (XLRS), also known as X-linked retinoschisis, is an X-linked recessive inherited retinal dystrophy that primarily affects males. Patients typically present with splitting of the retinal layers (particularly in the macula and peripheral retina), progressive vision loss, retinal structural abnormalities, and potential complications, such as vitreous hemorrhage and retinal detachment. XLRS is one of the common inherited eye disorders causing visual impairment in young males, with an estimated prevalence of 1 in 5,000 to 1 in 25,000 [1]. Depending on the severity of the clinical phenotype, XLRS generally manifests as a single major phenotype, although the type of mutation can influence disease severity. Most patients experience vision decline in early childhood, along with foveal schisis and common peripheral retinal schisis; some may develop retinal detachment or hemorrhage, with further deterioration in adulthood. Female carriers are usually asymptomatic or exhibit only mild manifestations [1-2]. The primary causative gene for XLRS is RS1, which encodes retinoschisin, a secreted cell adhesion protein. Retinoschisin maintains cell-cell adhesion in the retina, stabilizes retinal laminar architecture and synaptic integrity, and plays a critical role in normal retinal development, structural maintenance, and functional homeostasis. It is essential for photoreceptor-bipolar cell synaptic transmission, retinal layer organization, and visual signal processing [3]. RS1 interacts with negatively charged membrane lipids and the Na/K-ATPase complex on the cell surface to maintain retinal cell adhesion and laminar integrity. Its oligomeric structure (homo-octamers and paired octamers) is crucial for its adhesive function [4]. The protein is predominantly expressed in retinal photoreceptors (rods and cones) and bipolar cells, with additional expression in the pineal gland [3]. Studies have shown that RS1 participates in the regulation of the MAPK signaling pathway and apoptosis, thereby influencing photoreceptor-bipolar cell synaptic function [5].
The huRS1 mouse is a humanized model generated via gene editing, in which the murine Rs1 locus (from upstream of exon 1 to downstream of exon 3) is replaced with the human RS1 sequence (from upstream of exon 1 to downstream of the 3'UTR). This model facilitates research into the pathogenesis of X-linked retinoschisis (XLRS) and supports the preclinical pharmacological evaluation of RS1-targeted therapeutics.
Reference
Plössl K, Weber BH, Friedrich U. The X-linked juvenile retinoschisis protein retinoschisin is a novel regulator of mitogen-activated protein kinase signalling and apoptosis in the retina. J Cell Mol Med. 2017;21(4):768-780.
Hahn LC, van Schooneveld MJ, Wesseling NL, et al. X-Linked Retinoschisis: Novel Clinical Observations and Genetic Spectrum in 340 Patients. Ophthalmology. 2022;129(2):191-202.
Tolun G, Vijayasarathy C, Huang R, et al. Paired octamer rings of retinoschisin suggest a junctional model for cell-cell adhesion in the retina. Proc Natl Acad Sci U S A. 2016;113(19):5287-5292.
Vijayasarathy C, Zeng Y, Marangoni D, et al. Targeted Expression of Retinoschisin by Retinal Bipolar Cells in XLRS Promotes Resolution of Retinoschisis Cysts Sans RS1 From Photoreceptors. Invest Ophthalmol Vis Sci. 2022;63(11):8.
Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res. 2012;31(3):195-212.

Strain Strategy

The sequence from upstream of exon 1 to downstream of exon 3 of the mouse Rs1 was replaced with the sequence from upstream of exon 1 to downstream of 3’UTR of the human RS1.
Figure 1. Gene editing strategy of huRS1 mice.
Figure 1. Gene editing strategy of huRS1 mice.

Application Area

Screening, development, and preclinical evaluation of RS1-targeted drugs;
Research on the pathogenesis and therapies of X-linked juvenile retinoschisis (XLRS).
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research